-
Reporter uncovers how drug companies ‘make’ people into Alzheimer’s patients
In her latest investigative piece for The Lever, investigative journalist Jeanne Lenzer exposes the vast lobbying and marketing machine designed to turn healthy aging adults into “pre-Alzheimer’s” patients. Her reporting connected the dots between financial ties of high-level figures like Robert Redfield to patient recruitment through Facebook ads, to drugmakers and industry-funded groups pressuring Medicare…
-
Reporters uncover conflicts and dubious data on latest Alzheimer’s drug
The Alzheimer’s drug donanemab, brand name Kisunla. Image by Eli Lilly and Company A blockbuster story in the September 25 issue of The BMJ found major concerns surrounding the approval process, efficacy, and safety of the newest Alzheimer’s drug, donanemab (brand name Kisunla). An analysis by independent investigative journalists Jeanne Lenzer and Shannon Brownlee revealed…
-
What journalists should know before diving into drug investigations
Investigative journalists Jeanne Lenzer and Shannon Brownlee uncovered a trove of information about the recently approved Alzheimer’s drug donanemab, (brand name Kisunla). Their deeply reported article in the September 25 issue of The BMJ highlighted questionable clinical trial results to potentially unethical behavior — including payments and industry ties — among some FDA advisory committee…
Got any book recommendations?